- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02445339
Extended-release Naltrexone and Care Management for Alcohol Dependent Frequent Emergency Department Users
Novel Interventions for Alcohol Dependent Frequent Emergency Department Users: Phase IV, Randomized, Open-label, Non-placebo-controlled Study of Extended-release Naltrexone and Care Management on Healthcare Use, Drinking, & Quality of Life
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aim #1: To conduct a feasibility and acceptability study of XR-NTX+CM treatment in alcohol dependent patients with frequent ED use.
Hypothesis: Enrollment of a limited number of subjects will allow identification of optimal processes for a definitive trial.
Aim #2: To conduct an analysis of the effect of this intervention on healthcare utilization and engagement, drinking outcomes, quality of life, and consequences of drinking (initial analysis will be exploratory).
Hypothesis: Measuring changes in healthcare utilization, drinking metrics, and indicators of quality of life and consequences will provide preliminary data on intervention effect size on various outcomes of interest to inform the second phase, definitive trial.
Aim #3: To identify patient-level characteristics associated with effectiveness.
Hypothesis: Exploratory analysis of patient and system-level characteristics possibly associated with effectiveness will inform treatment choice to maximize the probability of successful outcome. Factors assessed will include data collected in ongoing investigations of pharmacotherapy for alcohol dependence, including mu opioid receptor (OPRM1) genotypes, to facilitate comparison across study populations and settings.
This a phase IV, randomized, open-label, non-placebo-controlled, single-center study of the feasibility, acceptability, and effect of initiating treatment in the ED with extended-release naltrexone 380mg intramuscular injection compared to standard care in subjects with severe alcohol use disorders (i.e. alcohol dependence) and frequent emergency department use. In the first two years, we will finalize study preparations, recruit and randomize 50 subjects for the pilot phase of this study. The duration of each subject's participation will be 12 months. Thereafter, in the second phase of study, we will enroll an additional 250 subjects (for a total of 300 subjects) to address remaining feasibility and acceptability concerns and test effects.
The study investigators (PI and RA) will collect process data, including barriers and facilitators encountered in the completion of all study procedures. For the following study procedures, study investigators (the PI and RAs) will enter data directly into New York University Langone Medical Center (NYULMC) internal REDCap system for use on portable tablet computers.
Synopsis of Study Procedures:
The following study procedures are described in greater detail elsewhere in this protocol.
Patients will be prescreened for potential eligibility and added to an automated alert system linked to ED registration by Bellevue Care Managers as part of an ongoing quality improvement initiative. When a potentially eligible patient presents to the ED, an automated page will be delivered to the study PI and Bellevue ED social work and care management staff, prompting consultation and potential referral of the patient to study investigators (PI/RA) for recruitment (See 4.3 Subject Recruitment and Screening). ED medical providers (inclusive of ED physicians, nurses, social workers, and care managers) will notify study investigators (PI/RA) when potentially eligible patients are present in the ED. The medical provider will introduce the PI/RA to clinically sober and medically stable patients who have given their permission to be approached. The PI/RA will describe the study, confirm capacity to consent using the University of California San Diego Brief Assessment of Capacity to Consent to Research (UBACC), and obtain written informed consent. The PI/RA will confirm eligibility by performing a chart and laboratory review (liver enzymes, pregnancy, urine drug screen), history and examination, and diagnostic interview to confirm alcohol dependence and assess for opioid use and chronic pain. The PI/RA will conduct research intake assessments and interview and collect blood for biomarker (5mL) and genetic (10mL) analyses. The PI/RA will randomize subjects to intervention (XR-NTX+CM) or Standard Care using a random number generator with randomly permuted blocks with allocations contained within opaque sealed envelopes.
- For subjects randomized to the Intervention Arm, the PI/RA will confirm the drug screen is negative for opioids prior to administering XR-NTX 380mg as an intramuscular gluteal injection. The PI/RA will facilitate a person-centered, harm-reduction-based motivational interview, , and psychosocial assessment/interview to inform subjects' care-management plans. Subjects will receive a one-week referral to Bellevue ambulatory care for initial Alcohol-Medical Management (MM) and will also be scheduled every 4 weeks (after most recent XR-NTX injection) for MM and XR-NTX injections. When possible, participants who miss MM-injection visits will be navigated to clinic upon their next ED presentation and/or may receive MM and XR-NTX in the ED. XR-NTX will be administered by the PI or a provider (physician, physician assistant, or registered nurse) who is trained in the administration of XR-NTX. The schedule for MM-Injection visits is weeks 4, 8, 12, 16, 20, and 24. Participants may be offered to continue XR-NTX treatment through this study for as many has 12 injections in total as we explore the feasibility, acceptability and potential benefits of extending treatment duration to 12 months. The schedule for potential additional MM-Injection visits is weeks 28, 32, 36, 40, and 44. Research assessment visits will occur at weeks 12, 24, and 48 and may be conducted up to 28 days prior to- or 90 days after- date in which research visits are due. During research visits, the PI/RA will repeat the assessments that were conducted at the initial enrollment visit plus adverse events and participant satisfaction and we will collect a 5mL blood sample to examine alcohol consumption biomarkers. Subject participation ends after the week-48 research visit.
- For subjects randomized to the Standard care arm, the PI/RA will provide referral to Bellevue ambulatory care for MM without further intervention. Research assessment visits will occur at weeks 12, 24, and 48 and may be conducted up to 28 days prior to- or 90 days after- date in which research visits are due. During research visits, the PI/RA will repeat the assessments that were conducted at the initial enrollment visit plus adverse events and participant satisfaction and we will collect a 5mL blood sample to examine alcohol consumption biomarkers. Subject participation ends after the week-48 research visit.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10016
- Bellevue Hospital Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
Subjects must meet all of the following criteria to be eligible for study enrollment:
English or Spanish speaking*
*Non-English Spanish speaking patients will not be enrolled initially until study documents have been translated, back translated, and approved by the Institutional Review Board (IRB).
- Emergency Department patient
- Aged 18-80
- Have had >4 emergency department visits within 12 months for 2 consecutive 12-month periods. Period of time can be extended by up to 6 months if incarcerated or institutionalized for ≥ 6 months.
- Meet Diagnostic and Statistical Manual version IV (DSM-IV) criteria for alcohol dependence or & DSM-V criteria for alcohol use disorder, severe.
- Have ≥2 days/week of heavy drinking (>4 drinks/day)
- Capable of giving informed consent.
Exclusion Criteria
Subjects who meet any of the following criteria will be ineligible for study enrollment:
- Active opioid dependence
- Acute or chronic pain requiring opioid treatment
- Acute liver injury (liver aminotransferase concentrations >5 times the upper limit of normal)
- Health condition considered unsafe for inclusion (at discretion of PI and/or attending physician)
- Lack of capacity or willingness to consent
- Currently prescribed pharmacotherapy for alcohol dependence (not including treatment of acute alcohol withdrawal syndrome)
- Previous significant adverse reaction to naltrexone or diluent
- Pregnant, nursing, or not using effective methods of birth control
- Prisoners (as defined by Office of Human Research Protection) at the time of enrollment ARE NOT ELIGIBLE for study entry. However, subjects who become prisoners after being enrolled will be included and not be withdrawn from the study. Patients on parole or probation are eligible for enrollment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Intervention Arm: XR-NTX+CM
XR-NTX+CM (Extended Release Naltrexone + Care Management)
|
The intervention arm will receive extended-release naltrexone (XR-NTX) 380mg (4 mL) to be administered as an intramuscular gluteal injection every 28 days up to 12 doses total.
Expedited referral to alcohol-medical management.
Care Management will include coordination of health care and social services for at least 12 months.
Harm-reduction counseling and motivational interviewing to identify and work towards goals.
The Standard care arm will receive an expedited alcohol-medical management referral.
Other Names:
|
No Intervention: Standard Care Arm
Standard Care/Alcohol-Medical Management (MM) Only
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Heavy Drinking Days
Time Frame: Month 3
|
Self-reported
|
Month 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Heavy Drinking Days
Time Frame: Month 6
|
Self-reported
|
Month 6
|
Number of Heavy Drinking Days
Time Frame: Month 12
|
Self-reported
|
Month 12
|
Short Inventory of Problems Related to Alcohol (SIP-2R) Score
Time Frame: Month 3
|
SIP-2R is a measure for assessing recent adverse consequences associated with alcohol use.
SIP-2R consists of 15 events that are scored from 0 (never) to 3 (daily or almost daily).
The total score range is 0-45; the higher the score, the more problems related to alcohol use.
|
Month 3
|
Short Inventory of Problems Related to Alcohol (SIP-2R) Score
Time Frame: Month 6
|
SIP-2R is a measure for assessing recent adverse consequences associated with alcohol use.
SIP-2R consists of 15 events that are scored from 0 (never) to 3 (daily or almost daily).
The total score range is 0-45; the higher the score, the more problems related to alcohol use.
|
Month 6
|
Short Inventory of Problems Related to Alcohol (SIP-2R) Score
Time Frame: Month 12
|
SIP-2R is a measure for assessing recent adverse consequences associated with alcohol use.
SIP-2R consists of 15 events that are scored from 0 (never) to 3 (daily or almost daily).
The total score range is 0-45; the higher the score, the more problems related to alcohol use.
|
Month 12
|
Carbohydrate-deficient Transferrin (CDT) Levels
Time Frame: Month 3
|
Month 3
|
|
Carbohydrate-deficient Transferrin (CDT) Levels
Time Frame: Month 6
|
Month 6
|
|
Carbohydrate-deficient Transferrin (CDT) Levels
Time Frame: Month 12
|
Month 12
|
|
Gamma-glutamyl Transferase (GGT) Levels
Time Frame: Month 3
|
Month 3
|
|
Gamma-glutamyl Transferase (GGT) Levels
Time Frame: Month 6
|
Month 6
|
|
Gamma-glutamyl Transferase (GGT) Levels
Time Frame: Month 12
|
Month 12
|
|
EuroQoL-5 Dimensions (EQ-5D) Score
Time Frame: Month 3
|
EQ-5D is a standardized measure of health-related quality of life.
A visual analogue scale is used to record an individual's valuation of defined EQ-5D profiles.
The total score range is 0-100; the higher the score, the better the health state (0=worst imaginable health state, 100=best imaginable health state).
|
Month 3
|
EuroQoL-5 Dimensions (EQ-5D) Score
Time Frame: Month 6
|
EQ-5D is a standardized measure of health-related quality of life.
A visual analogue scale is used to record an individual's valuation of defined EQ-5D profiles.
The total score range is 0-100; the higher the score, the better the health state (0=worst imaginable health state, 100=best imaginable health state).
|
Month 6
|
EuroQoL-5 Dimensions (EQ-5D) Score
Time Frame: Month 12
|
EQ-5D is a standardized measure of health-related quality of life.
A visual analogue scale is used to record an individual's valuation of defined EQ-5D profiles.
The total score range is 0-100; the higher the score, the better the health state (0=worst imaginable health state, 100=best imaginable health state).
|
Month 12
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ryan P McCormack, MD, NYU Langone Health
Publications and helpful links
General Publications
- McCormack RP, Williams AR, Goldfrank LR, Caplan AL, Ross S, Rotrosen J. Commitment to assessment and treatment: comprehensive care for patients gravely disabled by alcohol use disorders. Lancet. 2013 Sep 14;382(9896):995-7. doi: 10.1016/S0140-6736(12)62206-5. Epub 2013 Apr 19. No abstract available.
- McCormack RP, Hoffman LF, Wall SP, Goldfrank LR. Resource-limited, collaborative pilot intervention for chronically homeless, alcohol-dependent frequent emergency department users. Am J Public Health. 2013 Dec;103 Suppl 2(Suppl 2):S221-4. doi: 10.2105/AJPH.2013.301373. Epub 2013 Oct 22.
- McCormack RP, Hoffman LF, Norman M, Goldfrank LR, Norman EM. Voices of homeless alcoholics who frequent Bellevue Hospital: a qualitative study. Ann Emerg Med. 2015 Feb;65(2):178-86.e6. doi: 10.1016/j.annemergmed.2014.05.025. Epub 2014 Jun 26.
- McCormack RP, Gallagher T, Goldfrank LR, Caplan AL. Including frequent emergency department users with severe alcohol use disorders in research: assessing capacity. Ann Emerg Med. 2015 Feb;65(2):172-7.e1. doi: 10.1016/j.annemergmed.2014.09.027. Epub 2014 Oct 23.
- Hamilton BH, Sheth A, McCormack RT, McCormack RP. Imaging of frequent emergency department users with alcohol use disorders. J Emerg Med. 2014 Apr;46(4):582-7. doi: 10.1016/j.jemermed.2013.08.129. Epub 2014 Jan 10.
- Lee JD, Grossman E, DiRocco D, Truncali A, Hanley K, Stevens D, Rotrosen J, Gourevitch MN. Extended-release naltrexone for treatment of alcohol dependence in primary care. J Subst Abuse Treat. 2010 Jul;39(1):14-21. doi: 10.1016/j.jsat.2010.03.005. Epub 2010 Apr 2.
- Collins SE, Saxon AJ, Duncan MH, Smart BF, Merrill JO, Malone DK, Jackson TR, Clifasefi SL, Joesch J, Ries RK. Harm reduction with pharmacotherapy for homeless people with alcohol dependence: protocol for a randomized controlled trial. Contemp Clin Trials. 2014 Jul;38(2):221-34. doi: 10.1016/j.cct.2014.05.008. Epub 2014 May 17.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Emergency Department
- Alcohol Dependence
- Emergency Medicine
- Naltrexone
- Alcoholism
- Clinical Trial
- Physiological Effects of Drugs
- Narcotic Antagonists
- Alcohol Use Disorder
- Care Management
- Case Management
- Emergency Care Services
- Emergency Room
- Extended-release naltrexone
- Frequent Users
- Health Care Utilization
- Medical Management
- Population Health
- Public Health
- Vivitrol
- XR-NTX
- XR-NTX+CM
- Alcohol-Related Disorders
- Central Nervous System Agents
- Chemically-Induced Disorders
- Mental Disorders
- Peripheral Nervous System Agents
- Pharmacologic Actions
- Sensory System Agents
- Substance-Related Disorders
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Pathologic Processes
- Drinking Behavior
- Alcohol-Related Disorders
- Substance-Related Disorders
- Disease Attributes
- Alcohol Drinking
- Alcoholism
- Emergencies
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Sensory System Agents
- Narcotic Antagonists
- Alcohol Deterrents
- Naltrexone
Other Study ID Numbers
- 13-00928
- 1K23AA022989-01 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Dependence
-
University Hospital, LilleCompleted
-
Tel-Aviv Sourasky Medical CenterMinistry of Health, IsraelUnknownAlcohol-dependenceIsrael
-
Pop Test Oncology LLCBaylor College of Medicine; Michael E. DeBakey VA Medical Center; Congressionally... and other collaboratorsCompletedPotential Treatment for Alcohol Dependence-Alcohol InteractionUnited States
-
DynamiCare HealthNational Institute on Alcohol Abuse and Alcoholism (NIAAA); RANDActive, not recruitingAlcohol Dependence | Alcohol Use Disorder | Drug DependenceUnited States
-
National Institute on Alcohol Abuse and Alcoholism...CompletedAlcohol Abuse | Alcohol Dependence (Primary Condition)United States
-
University Hospital, Gentofte, CopenhagenCompleted
-
Massachusetts General HospitalCompletedAlcohol Dependence | Drug Abuse | Alcohol Abuse | Drug DependenceUnited States
-
Psychiatric Centre RigshospitaletThe Novavì outpatient clinics, CopenhagenRecruitingAddiction, Alcohol | Alcohol Dependence, in RemissionDenmark
-
University of WashingtonU.S. Army Medical Research and Development CommandCompletedAlcohol Dependence | Substance Abuse | Alcohol Abuse | Substance DependenceUnited States
-
Anders Fink-Jensen, MD, DMSciThe Novavì outpatient clinics, Copenhagen; Neurobiology Research Unit, Rigshospitalet... and other collaboratorsCompletedAddiction, Alcohol | Alcohol Dependence, in RemissionDenmark
Clinical Trials on XR-NTX+CM (Extended-Release Naltrexone plus Care Management)
-
University of Texas Southwestern Medical CenterNational Institute on Drug Abuse (NIDA)RecruitingCocaine Use DisorderUnited States
-
Friends Research Institute, Inc.RecruitingOpioid-use DisorderUnited States
-
Boston UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedAlcohol Dependence | Alcohol Use Disorder | Heavy DrinkingUnited States
-
NYU Langone HealthCompletedAlcohol DependenceUnited States
-
NYU Langone HealthHarvard Medical School (HMS and HSDM); National Institute on Drug Abuse (NIDA) and other collaboratorsRecruitingOpioid Use Disorder (OUD)United States
-
NYU Langone HealthNational Institute on Drug Abuse (NIDA); University of California, Los Angeles and other collaboratorsCompletedOpioid-Related Disorders | Heroin DependenceUnited States
-
University of PennsylvaniaAlkermes, Inc.Recruiting
-
University of OsloNorwegian Institute of Public Health; Oslo University Hospital; The Research... and other collaboratorsCompletedOpioid DependenceNorway
-
University of California, San FranciscoThe CARESTAR FoundationTerminatedSubstance Use | Alcohol Use Disorder | Alcohol Abuse or DependenceUnited States
-
National Institute on Drug Abuse (NIDA)Not yet recruitingMethamphetamine-dependence | Methamphetamine Abuse